{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:37:10Z","timestamp":1790609830519,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00066-019-01534-6","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T17:05:16Z","timestamp":1579885516000},"page":"356-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer","Verbessertes Behandlungsergebnis und geringere Hauttoxizit\u00e4t mit der intensit\u00e4tsmodulierten Strahlentherapie im Vergleich zur dreidimensionalen konventionellen Strahlentherapie beim Analkarzinom"],"prefix":"10.1007","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-3958","authenticated-orcid":false,"given":"Matthias","family":"Sauter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Lombriser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"B\u00fctikofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Kranzb\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan R.","family":"Vavricka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Misselwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"issue":"2","key":"1534_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cncr.20364","volume":"101","author":"LG Johnson","year":"2004","unstructured":"Johnson\u00a0LG, Madeleine\u00a0MM, Newcomer\u00a0LM, Schwartz\u00a0SM, Daling\u00a0JR (2004) Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973\u20132000. Cancer 101(2):281\u2013288","journal-title":"Cancer"},{"issue":"Suppl 3","key":"1534_CR2","doi-asserted-by":"publisher","first-page":"iii10","DOI":"10.1093\/annonc\/mdu159","volume":"25","author":"R Glynne-Jones","year":"2014","unstructured":"Glynne-Jones\u00a0R, Nilsson\u00a0PJ, Aschele\u00a0C, Goh\u00a0V, Peiffert\u00a0D, Cervantes\u00a0A, Arnold\u00a0D (2014) Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii10\u2013iii20","journal-title":"Ann Oncol"},{"issue":"3","key":"1534_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF02586980","volume":"17","author":"ND Nigro","year":"1974","unstructured":"Nigro\u00a0ND, Vaitkevicius\u00a0VK, Considine\u00a0B Jr. (1974) Combined therapy for cancer of the anal canal: a\u00a0preliminary report. Dis Colon Rectum 17(3):354\u2013356","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"1534_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink\u00a0H, Roelofsen\u00a0F, Eschwege\u00a0F, Rougier\u00a0P, Bosset\u00a0JF, Gonzalez\u00a0DG, Peiffert\u00a0D, van Glabbeke\u00a0M, Pierart\u00a0M (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a\u00a0phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J\u00a0Clin Oncol 15(5):2040\u20132049","journal-title":"J Clin Oncol"},{"issue":"9034","key":"1534_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","volume":"348","author":"UKCCCR Anal Cancer Trial Working Party","year":"1996","unstructured":"UKCCCR Anal Cancer Trial Working Party, UK Co-ordinating Committee on Cancer Research (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5\u2011fluorouracil, and mitomycin. Lancet 348(9034):1049\u20131054","journal-title":"Lancet"},{"issue":"2","key":"1534_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0002-9343(85)90428-0","volume":"78","author":"L Leichman","year":"1985","unstructured":"Leichman\u00a0L, Nigro\u00a0N, Vaitkevicius\u00a0VK, Considine\u00a0B, Buroker\u00a0T, Bradley\u00a0G, Seydel\u00a0HG, Olchowski\u00a0S, Cummings\u00a0G, Leichman\u00a0C (1985) Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med 78(2):211\u2013215","journal-title":"Am J Med"},{"issue":"9","key":"1534_CR7","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam\u00a0M, John\u00a0M, Pajak\u00a0TF, Petrelli\u00a0N, Myerson\u00a0R, Doggett\u00a0S, Quivey\u00a0J, Rotman\u00a0M, Kerman\u00a0H, Coia\u00a0L et\u00a0al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a\u00a0phase III randomized intergroup study. J\u00a0Clin Oncol 14(9):2527\u20132539","journal-title":"J Clin Oncol"},{"issue":"35","key":"1534_CR8","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","volume":"30","author":"LL Gunderson","year":"2012","unstructured":"Gunderson\u00a0LL, Winter\u00a0KA, Ajani\u00a0JA, Pedersen\u00a0JE, Moughan\u00a0J, Benson\u00a0AB, Thomas\u00a0CR, Mayer\u00a0RJ, Haddock\u00a0MG, Rich\u00a0TA et al (2012) Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin. J\u00a0Clin Oncol 30(35):4344\u20134351","journal-title":"J Clin Oncol"},{"issue":"15","key":"1534_CR9","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1200\/JCO.2014.55.4121","volume":"32","author":"RJ Mayer","year":"2014","unstructured":"Mayer\u00a0RJ, Venook\u00a0AP, Schilsky\u00a0RL (2014) Progress against GI cancer during the American Society of Clinical Oncology\u2019s first 50 years. J\u00a0Clin Oncol 32(15):1521\u20131530","journal-title":"J Clin Oncol"},{"issue":"5","key":"1534_CR10","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.ijrobp.2006.11.038","volume":"67","author":"T Vuong","year":"2007","unstructured":"Vuong\u00a0T, Kopek\u00a0N, Ducruet\u00a0T, Portelance\u00a0L, Faria\u00a0S, Bahoric\u00a0B, Devic\u00a0S (2007) Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys 67(5):1394\u20131400","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1534_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijrobp.2004.07.666","volume":"62","author":"DE Morris","year":"2005","unstructured":"Morris\u00a0DE, Emami\u00a0B, Mauch\u00a0PM, Konski\u00a0AA, Tao\u00a0ML, Ng\u00a0AK, Klein\u00a0EA, Mohideen\u00a0N, Hurwitz\u00a0MD, Fraas\u00a0BA et al (2005) Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 62(1):3\u201319","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"1534_CR12","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s00268-003-7105-6","volume":"27","author":"A Eisbruch","year":"2003","unstructured":"Eisbruch\u00a0A, Ship\u00a0JA, Dawson\u00a0LA, Kim\u00a0HM, Bradford\u00a0CR, Terrell\u00a0JE, Chepeha\u00a0DB, Teknos\u00a0TN, Hogikyan\u00a0ND, Anzai\u00a0Y et\u00a0al (2003) Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg 27(7):832\u2013837","journal-title":"World J Surg"},{"issue":"3","key":"1534_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1053\/srao.2002.00000","volume":"12","author":"MJ Zelefsky","year":"2002","unstructured":"Zelefsky\u00a0MJ, Fuks\u00a0Z, Leibel\u00a0SA (2002) Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol 12(3):229\u2013237","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"1534_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/cncr.11489","volume":"98","author":"LK Mell","year":"2003","unstructured":"Mell\u00a0LK, Roeske\u00a0JC, Mundt\u00a0AJ (2003) A survey of intensity-modulated radiation therapy use in the United States. Cancer 98(1):204\u2013211","journal-title":"Cancer"},{"issue":"2","key":"1534_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ijrobp.2005.02.030","volume":"63","author":"MT Milano","year":"2005","unstructured":"Milano\u00a0MT, Jani\u00a0AB, Farrey\u00a0KJ, Rash\u00a0C, Heimann\u00a0R, Chmura\u00a0SJ (2005) Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 63(2):354\u2013361","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1534_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","volume":"82","author":"LA Kachnic","year":"2012","unstructured":"Kachnic\u00a0LA, Tsai\u00a0HK, Coen\u00a0JJ, Blaszkowsky\u00a0LS, Hartshorn\u00a0K, Kwak\u00a0EL, Willins\u00a0JD, Ryan\u00a0DP, Hong\u00a0TS (2012) Dose-painted intensity-modulated radiation therapy for anal cancer: a\u00a0multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 82(1):153\u2013158","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1534_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","volume":"86","author":"LA Kachnic","year":"2013","unstructured":"Kachnic\u00a0LA, Winter\u00a0K, Myerson\u00a0RJ, Goodyear\u00a0MD, Willins\u00a0J, Esthappan\u00a0J, Haddock\u00a0MG, Rotman\u00a0M, Parikh\u00a0PJ, Safran\u00a0H et al (2013) RTOG 0529: a\u00a0phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5\u2011fluorouracil and mitomycin\u2011C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 86(1):27\u201333","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1534_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bpg.2016.06.005","volume":"30","author":"A Vinayan","year":"2016","unstructured":"Vinayan\u00a0A, Glynne-Jones\u00a0R (2016) Anal cancer\u2014what is the optimum chemoradiotherapy? Best Pract Res Clin Gastroenterol 30(4):641\u2013653","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"8","key":"1534_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00066-017-1159-0","volume":"193","author":"M Sauter","year":"2017","unstructured":"Sauter\u00a0M, Vavricka\u00a0SR, Keilholz\u00a0G, Heinrich\u00a0H, Winder\u00a0T, Kranzbuhler\u00a0H, Lombriser\u00a0N, Misselwitz\u00a0B (2017) Surveillance of anal carcinoma after radiochemotherapy : a retrospective analysis of 80 patients. Strahlenther Onkol 193(8):639\u2013647","journal-title":"Strahlenther Onkol"},{"key":"1534_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12876-016-0461-0","volume":"16","author":"M Sauter","year":"2016","unstructured":"Sauter\u00a0M, Keilholz\u00a0G, Kranzbuhler\u00a0H, Lombriser\u00a0N, Prakash\u00a0M, Vavricka\u00a0SR, Misselwitz\u00a0B (2016) Presenting symptoms predict local staging of anal cancer: a\u00a0retrospective analysis of 86 patients. BMC Gastroenterol 16:46","journal-title":"BMC Gastroenterol"},{"key":"1534_CR21","volume-title":"AJCC cancer staging handbook","year":"2010","unstructured":"Edge\u00a0SBBD, Compton\u00a0CC (eds) (2010) AJCC cancer staging handbook, 7th\u00a0edn. Springer, New York","edition":"7"},{"key":"1534_CR22","unstructured":"Common Terminology Criteria for Adverse Events v4.0 (CTCAE). https:\/\/www.eortc.be\/services\/doc\/ctc\/ctcae_4.03_2010-06-14_quickreference_5x7.pdf. Accessed: 29 January 2018"},{"issue":"15","key":"1534_CR23","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1002\/cncr.25901","volume":"117","author":"JG Bazan","year":"2011","unstructured":"Bazan\u00a0JG, Hara\u00a0W, Hsu\u00a0A, Kunz\u00a0PA, Ford\u00a0J, Fisher\u00a0GA, Welton\u00a0ML, Shelton\u00a0A, Kapp\u00a0DS, Koong\u00a0AC et al (2011) Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 117(15):3342\u20133351","journal-title":"Cancer"},{"issue":"2","key":"1534_CR24","first-page":"39","volume":"6","author":"MD Chuong","year":"2013","unstructured":"Chuong\u00a0MD, Freilich\u00a0JM, Hoffe\u00a0SE, Fulp\u00a0W, Weber\u00a0JM, Almhanna\u00a0K, Dinwoodie\u00a0W, Rao\u00a0N, Meredith\u00a0KL, Shridhar\u00a0R (2013) Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res 6(2):39\u201345","journal-title":"Gastrointest Cancer Res"},{"issue":"2","key":"1534_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.radonc.2013.03.012","volume":"107","author":"T Dasgupta","year":"2013","unstructured":"Dasgupta\u00a0T, Rothenstein\u00a0D, Chou\u00a0JF, Zhang\u00a0Z, Wright\u00a0JL, Saltz\u00a0LB, Temple\u00a0LK, Paty\u00a0PB, Weiser\u00a0MR, Guillem\u00a0JG et al (2013) Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a\u00a0propensity score analysis. Radiother Oncol 107(2):189\u2013194","journal-title":"Radiother Oncol"},{"key":"1534_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1748-717X-7-201","volume":"7","author":"CV Dewas","year":"2012","unstructured":"Dewas\u00a0CV, Maingon\u00a0P, Dalban\u00a0C, Petitfils\u00a0A, Peignaux\u00a0K, Truc\u00a0G, Martin\u00a0E, Khoury\u00a0C, Dewas\u00a0S, Crehange\u00a0G (2012) Does gap-free intensity modulated chemoradiation therapy provide a\u00a0greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? Radiat Oncol 7:201","journal-title":"Radiat Oncol"},{"issue":"4","key":"1534_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s13566-017-0326-3","volume":"6","author":"ET Fredman","year":"2017","unstructured":"Fredman\u00a0ET, Abdel-Wahab\u00a0M, Kumar\u00a0AMS (2017) Influence of radiation treatment technique on outcome and toxicity in anal cancer. J\u00a0Radiat Oncol 6(4):413\u2013421","journal-title":"J Radiat Oncol"},{"key":"1534_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1748-717X-9-113","volume":"9","author":"SA Koerber","year":"2014","unstructured":"Koerber\u00a0SA, Slynko\u00a0A, Haefner\u00a0MF, Krug\u00a0D, Schoneweg\u00a0C, Kessel\u00a0K, Kopp-Schneider\u00a0A, Herfarth\u00a0K, Debus\u00a0J, Sterzing\u00a0F (2014) Efficacy and toxicity of chemoradiation in patients with anal cancer\u2014a retrospective analysis. Radiat Oncol 9:113","journal-title":"Radiat Oncol"},{"issue":"3","key":"1534_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.clon.2016.10.005","volume":"29","author":"R Muirhead","year":"2017","unstructured":"Muirhead\u00a0R, Drinkwater\u00a0K, O\u2019Cathail\u00a0SM, Adams\u00a0R, Glynne-Jones\u00a0R, Harrison\u00a0M, Hawkins\u00a0MA, Sebag-Montefiore\u00a0D, Gilbert\u00a0DC (2017) Initial results from the Royal College of Radiologists\u2019 UK national audit of anal cancer radiotherapy 2015. Clin Oncol (R Coll Radiol) 29(3):188\u2013197","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"1534_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijrobp.2017.01.006","volume":"98","author":"EL Pollom","year":"2017","unstructured":"Pollom\u00a0EL, Wang\u00a0G, Harris\u00a0JP, Koong\u00a0AC, Bendavid\u00a0E, Bhattacharya\u00a0J, Chang\u00a0DT (2017) The impact of intensity modulated radiation therapy on hospitalization outcomes in the SEER-medicare population with anal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 98(1):177\u2013185","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1534_CR31","unstructured":"Kemmerer\u00a0EMA, Ranganna\u00a0S, Price\u00a0R, Komarnicky\u00a0L, Poli\u00a0J (2016) (P044) Comparison of toxicity-related breaks in treatment utilizing intensity-modulated radiation therapy (IMRT) vs three-dimensional (3D) Conformal techniques in the treatment of anal cancer. Oncology 30(Suppl\u00a01). https:\/\/www.cancernetwork.com\/ars-2016\/p044-comparison-toxicity-related-breaks-treatment-utilizing-intensity-modulated-radiation-therapy"},{"key":"1534_CR32","first-page":"469","volume":"8","author":"R Cendales","year":"2014","unstructured":"Cendales\u00a0R, Vasquez\u00a0J, Arbelaez\u00a0J, Bobadilla\u00a0I, Torres\u00a0F, Gaitan\u00a0A (2014) IMRT, RapidArc(R) and conformal radiotherapy in the treatment of tumours of the anal canal. Ecancermedicalscience 8:469","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"1534_CR33","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/IGC.0000000000000660","volume":"26","author":"Y Chang","year":"2016","unstructured":"Chang\u00a0Y, Yang\u00a0ZY, Li\u00a0GL, Li\u00a0Q, Yang\u00a0Q, Fan\u00a0JQ, Zhao\u00a0YC, Song\u00a0YQ, Wu\u00a0G (2016) Correlations between radiation dose in Bone marrow and hematological toxicity in patients with cervical cancer: a comparison of 3DCRT, IMRT, and rapidARC. Int J Gynecol Cancer 26(4):770\u2013776","journal-title":"Int J Gynecol Cancer"},{"key":"1534_CR34","doi-asserted-by":"publisher","first-page":"6285","DOI":"10.2147\/CMAR.S195989","volume":"11","author":"T Kumar","year":"2019","unstructured":"Kumar\u00a0T, Schernberg\u00a0A, Busato\u00a0F, Laurans\u00a0M, Fumagalli\u00a0I, Dumas\u00a0I, Deutsch\u00a0E, Haie-Meder\u00a0C, Chargari\u00a0C (2019) Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation. Cancer Manag Res 11:6285\u20136297","journal-title":"Cancer Manag Res"},{"issue":"22","key":"1534_CR35","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1002\/cncr.31721","volume":"124","author":"JK Elson","year":"2018","unstructured":"Elson\u00a0JK, Kachnic\u00a0LA, Kharofa\u00a0JR (2018) Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: a national cancer data base study. Cancer 124(22):4383\u20134392","journal-title":"Cancer"},{"issue":"16","key":"1534_CR36","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","volume":"30","author":"D Peiffert","year":"2012","unstructured":"Peiffert\u00a0D, Tournier-Rangeard\u00a0L, Gerard\u00a0JP, Lemanski\u00a0C, Francois\u00a0E, Giovannini\u00a0M, Cvitkovic\u00a0F, Mirabel\u00a0X, Bouche\u00a0O, Luporsi\u00a0E et al (2012) Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J\u00a0Clin Oncol 30(16):1941\u20131948","journal-title":"J Clin Oncol"},{"issue":"19","key":"1534_CR37","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris\u00a0RL, Blumenschein\u00a0G Jr., Fayette\u00a0J, Guigay\u00a0J, Colevas\u00a0AD, Licitra\u00a0L, Harrington\u00a0K, Kasper\u00a0S, Vokes\u00a0EE, Even\u00a0C et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N\u00a0Engl J Med 375(19):1856\u20131867","journal-title":"N Engl J Med"},{"issue":"2","key":"1534_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid\u00a0O, Robert\u00a0C, Daud\u00a0A, Hodi\u00a0FS, Hwu\u00a0WJ, Kefford\u00a0R, Wolchok\u00a0JD, Hersey\u00a0P, Joseph\u00a0RW, Weber\u00a0JS et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N\u00a0Engl J Med 369(2):134\u2013144","journal-title":"N Engl J Med"},{"issue":"4","key":"1534_CR39","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","volume":"18","author":"VK Morris","year":"2017","unstructured":"Morris\u00a0VK, Salem\u00a0ME, Nimeiri\u00a0H, Iqbal\u00a0S, Singh\u00a0P, Ciombor\u00a0K, Polite\u00a0B, Deming\u00a0D, Chan\u00a0E, Wade\u00a0JL et al (2017) Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a\u00a0multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446\u2013453","journal-title":"Lancet Oncol"},{"issue":"4","key":"1534_CR40","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s00066-018-1272-8","volume":"194","author":"D Martin","year":"2018","unstructured":"Martin\u00a0D, Rodel\u00a0C, Fokas\u00a0E (2018) Nivolumab for pretreated metastatic anal cancer : immune checkpoint blockade is also advised in combination with radiochemotherapy. Strahlenther Onkol 194(4):356\u2013357","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"1534_CR41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00066-019-01444-7","volume":"195","author":"D Martin","year":"2019","unstructured":"Martin\u00a0D, Rodel\u00a0C, Fokas\u00a0E (2019) Chemoradiotherapy for anal cancer: are we as good as we think? Strahlenther Onkol 195(5):369\u2013373","journal-title":"Strahlenther Onkol"},{"issue":"18","key":"1534_CR42","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.ejca.2015.08.029","volume":"51","author":"O Leon","year":"2015","unstructured":"Leon\u00a0O, Guren\u00a0MG, Radu\u00a0C, Gunnlaugsson\u00a0A, Johnsson\u00a0A (2015) Phase I study of cetuximab in combination with 5\u2011fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Eur J Cancer 51(18):2740\u20132746","journal-title":"Eur J Cancer"},{"issue":"7","key":"1534_CR43","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","volume":"35","author":"MK Garg","year":"2017","unstructured":"Garg\u00a0MK, Zhao\u00a0F, Sparano\u00a0JA, Palefsky\u00a0J, Whittington\u00a0R, Mitchell\u00a0EP, Mulcahy\u00a0MF, Armstrong\u00a0KI, Nabbout\u00a0NH, Kalnicki\u00a0S et al (2017) Cetuximab plus Chemoradiotherapy in immunocompetent patients with anal carcinoma: a Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J\u00a0Clin Oncol 35(7):718\u2013726","journal-title":"J Clin Oncol"},{"issue":"1","key":"1534_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/01.coc.0000139939.60056.42","volume":"28","author":"V Kouloulias","year":"2005","unstructured":"Kouloulias\u00a0V, Plataniotis\u00a0G, Kouvaris\u00a0J, Dardoufas\u00a0C, Gennatas\u00a0C, Uzunoglu\u00a0N, Papavasiliou\u00a0C, Vlahos\u00a0L (2005) Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a\u00a0phase II randomized trial. Am J Clin Oncol 28(1):91\u201399","journal-title":"Am J Clin Oncol"},{"key":"1534_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-018-1396-x","author":"OJ Ott","year":"2019","unstructured":"Ott\u00a0OJ, Schmidt\u00a0M, Semrau\u00a0S, Strnad\u00a0V, Matzel\u00a0KE, Schneider\u00a0I, Raptis\u00a0D, Uter\u00a0W, Grutzmann\u00a0R, Fietkau\u00a0R (2019) Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-018-1396-x","journal-title":"Strahlenther Onkol"},{"issue":"16","key":"1534_CR46","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"299","author":"JA Ajani","year":"2008","unstructured":"Ajani\u00a0JA, Winter\u00a0KA, Gunderson\u00a0LL, Pedersen\u00a0J, Benson\u00a0AB 3rd, Thomas\u00a0CR Jr., Mayer\u00a0RJ, Haddock\u00a0MG, Rich\u00a0TA, Willett\u00a0C (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a\u00a0randomized controlled trial. JAMA 299(16):1914\u20131921","journal-title":"JAMA"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-019-01534-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-019-01534-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-019-01534-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:13:52Z","timestamp":1611360832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-019-01534-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1007\/s00066-019-01534-6","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,24]]},"assertion":[{"value":"27 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Sauter, N.\u00a0Lombriser, S.\u00a0B\u00fctikofer, G.\u00a0Keilholz, H.\u00a0Kranzb\u00fchler, H.\u00a0Heinrich, G.\u00a0Rogler, S.R.\u00a0Vavricka, and B.\u00a0Misselwitz declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}